Femme Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To demonstrate clinical efficacy of the investigational trifunctional antibody (ertumaxomab) for the treatment of hormone therapy refractory advanced or metastatic breast cancer tumors (stage IIIb or IV) which are known to express HER-2/neu (1+ or 2+).
Critère d'inclusion
- Cáncer de mama avanzado o metastásico (estadio IIIb o IV) que se sepa que expresa HER-2/neu (1+ o 2+) y que es resistente a hormonoterapia,Hormone therapy refractory advanced or metastatic breast cancer tumors (stage IIIb or IV) which are known to express HER-2/neu (1+ or 2+)